Invesco backs infirst with £25m

The fresh capital will be used for the launch of infirst's medicines into the $20bn cough, cold and pain consumer healthcare markets.

The company has developed a portfolio of pipeline products. Its strategic focus is on rapid product development, swift pathways to regulatory approval and IP protection.

Company
Founded in 2012 and based in London, British healthcare company infirst will launch its first product, a cocoa-flavoured cough liquid, in Europe.

The company is also developing a non-narcotic/non-opioid cough treatment, which is in a Phase III clinical study, targeted for a 2015 market launch.

The US rights to infirst's cough-related IP have been out-licensed to Nasdaq-listed US company Pernix Therapeutics Holdings, Inc. The company is also developing an ibuprofen-based product for the treatment of inflammatory pain, to which it has the global rights.

People
Manfred Scheske is the CEO of infirst. Andrew Waters is the chief financial officer of infirst's management team. Lynn Drummond, Gregory Stoloff and Kimbell Duncan will join infirst's board.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Now researching
• Early-stage
• Healthcare
• United Kingdom